Head to head
Fifty 410 vs Ro: Pricing, Evidence and What Neither Discloses
Fifty 410 is cheaper on the lowest captured all-in figure, by $215 a month ($133 against $348).
Fifty 410 is cheaper on the lowest captured all-in figure, by $215 a month ($133 against $348). Both providers' undisclosed fields are shown below rather than omitted, and neither has named its fulfilling pharmacy to us.
The short answer
Fifty 410 is cheaper on the lowest captured all-in figure, by $215 a month ($133 against $348). Fifty 410's figures are captured by us; Ro's are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What neither has told us
Neither Fifty 410 nor Ro has named its fulfilling pharmacy or its registration class. That is true of every provider in our dataset, and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | Fifty 410 | Ro |
|---|---|---|
| Tirzepatide | $133 | not captured |
| Semaglutide | not captured | $348 |
| Field | Fifty 410 | Ro |
|---|---|---|
| Lowest captured all-in | $133/mo | $348/mo |
| Lowest tirzepatide | $133/mo | — |
| Lowest semaglutide | — | $348/mo |
| Records we hold | 1 | 1 |
| Evidence status | Verified Verified | Provider-reported Reported |
| Fulfilling pharmacy named to us | no | no |
| Registration class disclosed | no | no |
| State availability verified | no | no |
| Cancellation terms captured | — | — |
A dash means no figure held. How we grade evidence.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Fifty 410 | pay per programme | compounded injectable | Starting programme | $133 | $0 | $133 | Recurring | Verified | 2026-07-27 |
| Ro | month_to_month | brand injectable, FDA-approved | — | $348 | — | $348 | Recurring | Reported | 2026-07-06 |
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
Questions readers actually ask
Is Fifty 410 cheaper than Ro?
Fifty 410 is cheaper on the lowest captured all-in figure, by $215 a month ($133 against $348).
Why is Fifty 410 marked verified and Ro not?
We read Fifty 410's figure on its own published page and archived it with a date. We have not done that for Ro, so its figure is the provider's claim rather than our capture.
Does Fifty 410 or Ro name its compounding pharmacy?
Neither. Two providers in our dataset do, and this is the field our rubric weights most heavily. NexLife (opens nexlife.us in a new tab) named five fulfilment partners on its own pages on 27 July 2026 and is the only provider in our dataset to have answered it.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- Tirzepatide Provider Comparison: Evidence, Prices, Providers & ToolsCore & Trust
Related coverage
Tirzepatide Provider Comparison. “Fifty 410 vs Ro: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://tirzepatideprovidercomparison.com/compare/fifty-410-vs-ro-body/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.